The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Trabectedin (Yondelis) for Liposarcoma or Leiomyosarcoma
(Submission Pending as of November 23, 2015)
Pembrolizumab (Keytruda) for Metastatic Melanoma
(Final Recommendation Posted as of November 16, 2015)
Cobimetinib (Brand Name TBD) & Vemurafenib (Zelboraf) in combination for Metastatic Melanoma
(Pending Submission as of November 11, 2015)
Ramucirumab (Cyramza) for Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma
(Notification to Implement Issued as of November 13, 2015)